137 episodes

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerVoice Clinical Pharmacology Audio PeerVoice

    • Science

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    Defining Control in Moderate-to-Severe Asthma: Where Are We Now and What Can We Do?

    Defining Control in Moderate-to-Severe Asthma: Where Are We Now and What Can We Do?

    Go online to peervoice.com/XEF860 to view the entire programme with slides. After completing “Defining Control in Moderate-to-Severe Asthma: Where Are We Now and What Can We Do?”, participants will be able to: Recognise limitations regarding current concepts of asthma control; Understand the role of biomarkers in the treatment of moderate-to-severe asthma; and Develop targeted strategies for assessing and managing moderate-to-severe asthma.

    • 18 min
    Unmet Needs in Familial Mediterranean Fever (FMF): Real-Life Data, the Patient Perspective, and the Role of Anti–IL-1 Therapy

    Unmet Needs in Familial Mediterranean Fever (FMF): Real-Life Data, the Patient Perspective, and the Role of Anti–IL-1 Therapy

    Go online to peervoice.com/AJN860 to view the entire programme with slides. After completing “Unmet Needs in Familial Mediterranean Fever (FMF): Real-Life Data, the Patient Perspective, and the Role of Anti–IL-1 Therapy”, participants will be able to: Characterise the incidence and impact of colchicine resistance among patients with FMF; Understand disease burden from the perspective of the patient; and Analyse the long-term clinical and quality-of-life (QoL) data for anti–IL-1 therapy in colchicine-resistant FMF.

    • 59 min
    Best Practices for MET Mutation Testing in NSCLC: The Role of the Oncologist and the Pathologist

    Best Practices for MET Mutation Testing in NSCLC: The Role of the Oncologist and the Pathologist

    Go online to peervoice.com/ATJ860 to view the entire programme with slides. After completing “Best Practices for MET Mutation Testing in NSCLC: The Role of the Oncologist and the Pathologist”, participants will be able to: Discuss the rationale for MET biomarker testing in patients with non–small-cell lung cancer (NSCLC); Describe current testing modalities for patients with NSCLC and recent advances in identifying novel mutations; and Apply MET biomarker testing as standard of care for patients with NSCLC.

    • 16 min
    Novel Therapies for Patients With DLBCL: What Does the Future Hold?

    Novel Therapies for Patients With DLBCL: What Does the Future Hold?

    Go online to peervoice.com/VYU860 to view the entire programme with slides. After completing “Novel Therapies for Patients With DLBCL: What Does the Future Hold?”, participants will be able to: Explain the rationale for novel therapeutic options for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL); Evaluate the risk-benefit profiles of current and emerging therapies for the management of R/R DLBCL; and Incorporate available data on the use of novel anti-CD19 antibody strategies to treat R/R DLBCL into clinical practice.

    • 1 hr 4 min
    New Targets in Heart Failure: Congress Updates on SGLT2 Inhibitors

    New Targets in Heart Failure: Congress Updates on SGLT2 Inhibitors

    Go online to peervoice.com/QTK860 to view the entire programme with slides. After completing “New Targets in Heart Failure: Congress Updates on SGLT2 Inhibitors”, participants will be able to: Explain the rationale for SGLT2 inhibition in patients with heart failure (HF); Analyse clinical evidence for safety and efficacy of medical therapy such as SGLT2 inhibitors in patients with HF; and Describe the potential clinical implications of novel strategies on outcomes in HF.

    • 12 min
    Evaluating the Evidence for SGLT2 Inhibition in CKD

    Evaluating the Evidence for SGLT2 Inhibition in CKD

    Go online to peervoice.com/QSX860 to view the entire programme with slides. After completing “Evaluating the Evidence for SGLT2 Inhibition in CKD”, participants will be able to: Explain the rationale for SGLT2 inhibition in patients with chronic kidney disease (CKD), based on mechanisms of action; Analyse clinical evidence for safety and efficacy of oral therapy such as SGLT2 inhibitors in patients with CKD; and Describe the potential clinical implications of novel strategies on outcomes in CKD.

    • 19 min

Top Podcasts In Science

Listeners Also Subscribed To